EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Superactivation of p53 Using Drug Combinations and New Insights into p53 Functions and Anticancer Therapy

Marek Rusin iD, Małgorzata Krześniak iD, Barbara Łasut-Szyszka iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27208964 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Marek Rusin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Preclinical Models, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-101 Gliwice, Poland. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The p53 tumour suppressor protein exerts its influence on cells by regulating the expression of more than one thousand genes. To study p53 functions, cells are treated with various p53 activators, mostly established or experimental anticancer drugs. Some of these substances strongly collaborate in the activation of p53, which is manifested by a pronounced increase in the number of p53 molecules phosphorylated at both the amino and carboxyl terminus, a sign of p53 activation. Another manifestation of this collaboration is an increase in the number of upregulated genes. A good example of apparent synergy is the treatment of cells with actinomycin D and nutlin-3a, although other drug combinations show similar effects. The molecular mechanism underlying this collaboration is not precisely known. This superactivation of p53 has potential therapeutic applications. For example, it strongly sensitises cancer cells to apoptosis induced by FASLG, a ligand of the FAS death receptor. Moreover, superactivated p53 enables the identification of new p53 target genes, which helps us to better understand poorly studied p53 functions, such as the regulation of innate immunity, modification of cell microenvironments, removal of apoptotic bodies, tissue repair, and hormone production. However, innovative drug combinations targeting the p53 pathway have yet to be successfully translated into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Antineoplastic AgentsNeoplasmsHumansAnimalsApoptosisGene Expression Regulation, NeoplasticDrug SynergismImidazolesPiperazines

Stichwörter der Autor:innen

DRAXINSLAMF7SOCS1death receptorsdrug synergyinnate immunityp53

Substanzen

Tumor Suppressor Protein p53Antineoplastic Agentsnutlin 3ImidazolesPiperazines

Autor:innen und Institutionen

  • Laboratory of Preclinical Models, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-101 Gliwice, Poland.

ORCID-Profile: Marek Rusin, Małgorzata Krześniak, Barbara Łasut-Szyszka

Zitieren

APA

Rusin, M., Krześniak, M., & Łasut-Szyszka, B. (2026). Superactivation of p53 Using Drug Combinations and New Insights into p53 Functions and Anticancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27208964

Vancouver

Rusin M, Krześniak M, Łasut-Szyszka B. Superactivation of p53 Using Drug Combinations and New Insights into p53 Functions and Anticancer Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27208964

BibTeX
@article{Rusin2026,
  author = {Rusin, Marek and Krześniak, Małgorzata and Łasut-Szyszka, Barbara},
  title = {Superactivation of p53 Using Drug Combinations and New Insights into p53 Functions and Anticancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27208964}
}
Kostenlos starten →